Claims for Patent: 9,701,943

Summary for Patent: 9,701,943

Title:	Genetic variant of cytomegalovirus (CMV)
Abstract:	The present invention relates to a genetic variant of CMV, said genetic variant lacking intron 2 of the IE region of CMV (CMV IE.DELTA.i2) The present invention also relates to various uses of this genetic variant as well as RNA splice variants transcribed therefrom, and proteins expressed from the RNA splice variants, such as in the diagnosis of a CMV related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the CMV IE.DELTA.i2 virus with a human sample and prevention and treatment through targeting of unique CMV IE proteins for immunotherapy and vaccination.
Inventor(s):	Naucler; Cecilia (Bromma, SE)
Assignee:
Application Number:	14/111,247
Patent Claims:	1. A method for determining the presence or absence of a substance associated with a genetic variant of human cytomegalovirus (CMV) in a biological sample from a mammal suffering from or suspected of having cancer, wherein said genetic variant lacks intron 2 of the Immediate Early (IE) gene loci of the CMV genome (CMV IE.DELTA.i2), comprising: performing a technical analysis of a biological sample from a mammal suffering from or suspected of having cancer, to determine if the sample comprises a substance associated with said genetic variant selected from the group consisting of (i) said genetic variant, (ii) one or more RNA splice variants transcribed from said genetic variant, and (iii) one or more proteins translated from said one or more splice variants. 2. The method of claim 1, wherein the presence or absence of said substance is determined by the presence or absence in said sample of antibodies directed thereto, or by the presence or absence in said sample of T cells directed against said substance. 3. The method of claim 1, wherein said biological sample is selected from the group consisting of a blood sample, a tissue sample, a stem cell sample, an organ transplant graft sample, a semen sample, a urine sample, a saliva sample, a cell swab, and a breast milk sample. 4. The method of claim 1, wherein said technical analysis comprises a DNA detection method. 5. The method of claim 1, wherein said technical analysis comprises polymerase chain reaction (PCR) or fluorescent in-situ hybridization. 6. The method of claim 5, wherein said technical analysis comprises PCR, and wherein said PCR is performed by amplifying at least a part of exon 2 and 3 of the IE gene of CMV. 7. The method of claim 1, wherein the technical analysis comprises using one or more antibodies. 8. The method of claim 7, wherein said one or more antibodies are directed against one or more proteins translated from exon 2 and exon 3 of the IE region of the CMV genome. 9. The method of claim 1, wherein the presence or absence of said substance is determined using the nucleic acid sequence set forth in SEQ ID NO:1. 10. The method of claim 1, wherein said genetic variant lacking intron 2 lacks SEQ ID NO:17. 11. The method of claim 1, wherein said substance is said genetic variant, wherein said genetic variant lacks the nucleic acid sequence from position 173903 to position 174019 of Merlin reference sequence AY 446894.2 (wild type CMV) (SEQ ID NO: 41). 12. The method of claim 1, wherein said substance is said genetic variant, wherein said genetic variant comprises nucleic acid sequences encoding exon 2 (residues 1-29 of SEQ ID NO:38) and exon 3 (residues 30-85 of SEQ ID NO:38) of CMV. 13. The method of claim 1, wherein said substance is an RNA splice variant obtained by transcription of a CMV IE.DELTA.i2 nucleic acid that lacks SEQ ID NO:17. 14. The method of claim 1, wherein said substance is an RNA splice variant that consists of exons 2 and 3 of the CMV IE gene. 15. The method of claim 1, wherein said substance is an RNA splice variant that consists of exons 2, 3 and 4 of the CMV IE gene. 16. The method of claim 1, wherein said substance is an RNA splice variant that consists of exons 2, 3 and 5 of the CMV IE gene. 17. The method of claim 1, wherein said substance is a protein encoded by said genetic variant, wherein said protein is selected from the group consisting of CMV proteins having a size of approximately 150, 125, 76, 75, 72, 55, 53, 50, 40, 38, 36, 32, 31, 30, 25, 19, 18, 14, 12 and 10 kDa. 18. The method of claim 1, wherein said substance is a protein encoded by said RNA splice variant, wherein said protein is selected from the group consisting of CMV proteins having a size of approximately 150, 125, 76, 75, 72, 55, 53, 50, 40, 38, 36, 32, 31, 30, 25, 19, 18, 14, 12 and 10 kDa.

Details for Patent 9,701,943

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2031-04-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2031-04-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2031-04-15